vibativ Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Vibativ, and what generic alternatives are available?
Vibativ is a drug marketed by Cumberland and is included in one NDA. There is one patent protecting this drug.
This drug has thirty-three patent family members in eighteen countries.
The generic ingredient in VIBATIV is telavancin hydrochloride. One supplier is listed for this compound. Additional details are available on the telavancin hydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Vibativ
Vibativ was eligible for patent challenges on September 11, 2013.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be January 1, 2027. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for vibativ?
- What are the global sales for vibativ?
- What is Average Wholesale Price for vibativ?
Summary for vibativ
| International Patents: | 33 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 16 |
| Clinical Trials: | 14 |
| Patent Applications: | 8 |
| Drug Prices: | Drug price information for vibativ |
| What excipients (inactive ingredients) are in vibativ? | vibativ excipients list |
| DailyMed Link: | vibativ at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for vibativ
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for vibativ
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Aaron Cook | Phase 4 |
| Joseph L. Kuti, PharmD | Phase 4 |
| Cumberland Pharmaceuticals, Inc. | Phase 4 |
Pharmacology for vibativ
| Drug Class | Lipoglycopeptide Antibacterial |
US Patents and Regulatory Information for vibativ
vibativ is protected by one US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of vibativ is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting vibativ
Hydrochloride salts of a glycopeptide phosphonate derivative
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cumberland | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-001 | Sep 11, 2009 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Cumberland | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-002 | Sep 11, 2009 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for vibativ
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Cumberland | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-001 | Sep 11, 2009 | ⤷ Sign Up | ⤷ Sign Up |
| Cumberland | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-002 | Sep 11, 2009 | ⤷ Sign Up | ⤷ Sign Up |
| Cumberland | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-001 | Sep 11, 2009 | ⤷ Sign Up | ⤷ Sign Up |
| Cumberland | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-001 | Sep 11, 2009 | ⤷ Sign Up | ⤷ Sign Up |
| Cumberland | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-002 | Sep 11, 2009 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for vibativ
See the table below for patents covering vibativ around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| South Korea | 20060094082 | HYDROCHLORIDE SALTS OF A GLYCOPEPTIDE PHOSPHONATE DERIVATIVE | ⤷ Sign Up |
| Slovakia | 287470 | ⤷ Sign Up | |
| Japan | 2008222718 | REDUCTIVE ALKYLATION PROCESS ON GLYCOPEPTIDE | ⤷ Sign Up |
| Mexico | PA02012745 | DERIVADOS DE FOSFONATOS DE GLICOPEPTIDOS. (GLYCOPEPTIDE PHOSPHONATE DERIVATIVES.) | ⤷ Sign Up |
| World Intellectual Property Organization (WIPO) | 0198328 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for vibativ
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1292612 | CA 2011 00033 | Denmark | ⤷ Sign Up | PRODUCT NAME: TELAVANCIN, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER TELAVANCIN HYDROCHLORID |
| 1292612 | 11C0051 | France | ⤷ Sign Up | PRODUCT NAME: TELAVANCINE; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902 |
| 1292612 | 91908 | Luxembourg | ⤷ Sign Up | 91908, EXPIRES: 20260501 |
| 1292612 | PA2012002,C1292612 | Lithuania | ⤷ Sign Up | PRODUCT NAME: TELAVANCINUM; REGISTRATION NO/DATE: EU/1/11/705/001, 2011 09 02 EU/1/11/705/002 20110902 |
| 1292612 | 417 | Finland | ⤷ Sign Up | |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
